Patient groups urge Congress to reauthorize Prescription Drug User Fee Act, improve clinical trial diversity

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death

I always liked poetry, but I was never a poet. I had to marry into that.

August 08, 2025

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

EPCORE FL-1 phase III trial results show that subcutaneous epcoritamab in combination with rituximab and lenalidomide reduced the risk of disease progression or death by 79% for patients with relapsed/refractory follicular lymphoma.

August 08, 2025

Vol.51 No.31

Podcast

In The Headlines: A good week for NIH, a bad week for Vinay Prasad

While doing somewhat-routine reporting on this year’s Senate Appropriations Committee bills, Paul Goldberg, editor and publisher of The Cancer Letter, quickly realized that he was seeing a full bipartisan rejection of President Donald J. Trump’s plan to defund and therefore dismantle biomedical research in the United States.

August 06, 2025

Vol.51 No.30

Clinical Conversation with The Cancer Letter

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

The first large cancer screening/early detection initiative to be launched in 2025—the NCI-funded Vanguard study of multi-cancer detection tests—has started accruing patients through nine sites across the U.S.

July 25, 2025

Vol.51 No.29

By Sara Willa Ernst, Jacquelyn Cobb and Paul Goldberg

City of Hope brings evidence-based approaches to integrative oncology

The landscape of cancer care is evolving rapidly, with growing recognition that optimal patient outcomes require a whole-person care approach that goes beyond cytotoxic and targeted therapies.

Ohio State launches pancreatic cancer trial via telehealth

The Ohio State University Comprehensive Cancer has launched a first-of-its-kind clinical trial.

July 18, 2025

Vol.51 No.28

Patient groups urge Congress to reauthorize Prescription Drug User Fee Act, improve clinical trial diversity

YOU MAY BE INTERESTED IN

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

In The Headlines: A good week for NIH, a bad week for Vinay Prasad

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

City of Hope brings evidence-based approaches to integrative oncology

Ohio State launches pancreatic cancer trial via telehealth

Renew today!

Subscriber content

Never miss an issue!

Login

Patient groups urge Congress to reauthorize Prescription Drug User Fee Act, improve clinical trial diversity

YOU MAY BE INTERESTED IN

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and lossHer collection, “To See Yourself As You Vanish,” will be published three years after her death

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

In The Headlines: A good week for NIH, a bad week for Vinay Prasad

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

City of Hope brings evidence-based approaches to integrative oncology

Ohio State launches pancreatic cancer trial via telehealth

Never miss an issue!

Login

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death